CA-DENODO
27.10.2021 09:02:12 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced that its annual global user conference, Denodo DataFest 2021 , which was held in North America (NA), EMEA and APAC, attracted 5,000 worldwide registrants. While DataFest APAC and EMEA were held in a virtual format this year, DataFest NA was conducted in a hybrid mode, attracting hundreds of attendees online and in-person in New York. The attendees, made up of Denodo customers, partners, and subject matter experts, discussed the future of data and analytics involving topics such as logical data fabric, cloud modernization, data mesh, AI/ML and more.
Forrester VP and Principal Analyst Michele Goetz kicked off the conference presenting the Total Economic Impact™ of Data Virtualization using Denodo Platform , while David Loshin, President of Knowledge Integrity at TDWI presented the importance of Logical Data Fabric for Hybrid Cloud. Click here to watch the full conference line up.
“While we are not entirely over the pandemic yet, I was personally touched and thrilled to see the excitement among our customers and partners, both in-person and online who joined us to make this year’s DataFest such a success,” said Ravi Shankar, SVP and CMO at Denodo. “Our customers, partners, and internal subject matter experts presented and discussed topics such as why data lakehouse needs a logical architecture, application of advanced semantics in multi/hybrid cloud scenarios, the need for performance acceleration for advanced analytics and data science, to name a few. It was great to see the strength of our customers’ use cases as the Innovation Award polling saw stiff competition among the finalists.”
Winners and Finalists of Denodo Data Innovation Awards 2021 include:
- North America – Winner Ryan Fattini from City Furniture , for their Digitizing City Furniture’s Business Model use case; finalist Jonathan Paul from Fifth Third Bank , for their Digital Transformation and Regulatory Excellence use case.
- APAC – Winner Shaurya Bhasin from GeTS , for their Logical Data Fabric use case; finalist Wilbertus Darmadi from Toyota Astra Motor , for their Data Catalog based Self-Service use case.
- EMEA – Winner Jan Swanepoel from NedBank , for their Largest Data Warehouse on the Planet use case; finalist, Luis Guadarrama from Engie for their data-driven initiatives with Logical Data Fabric use case.
“Winning this year’s Data Innovation Award for the APAC region was a great validation of the strength of our data virtualization use cases and the results we were able to achieve,” said Shaurya Bhasin, Data Platform Lead at GeTS. “In building our unified data platform we were able to offer secure and well governed data access in a multi-cloud scenario. The Denodo Platform is as an important piece of the architecture and I was happy to share our story with the DataFest audience and perhaps it resonated with the audience!”
While Denodo customers played a pivotal role in sharing their business and technical use cases with the audience, it was the amazing network of Denodo Partners which included Accenture, Advanced Analytic Service, Axians, BDO (SimplicityBI), BITanium, CIO Academy Asia (CIOAA), Cognizant, Cyberionix, Dai Nippon Printing, DAMA, Devfacto, EY, Hitachi Solutions, Indium Software, Insight Technology, iOCO, IQZ Systems, JEMS, Mainline, MDI Novare Technologies, Nippon Systemware, NS Solutions, Nucleus Software, Q Perior, Servian, Sirius, UST, Wipro and Zeal that made an event of this scale possible. Denodo’s technology partner AWS took part in a Fireside chat to discuss the important of Logical Data Fabric for successful cloud migration.
Please tweet: #datavirtualization leader Denodo announce the winners of 4th annal Data Innovation Awards During #DataFest 2021. Audience vote @CityFurniture, @CLGeTS and @Nedbank for the most innovative use cases
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
